Search - tctmd.com

Displaying 161 - 180 of 496

Sort: Relevancy | Date

Presentation TCT 2018

Early Experiences with the New TriGUARD 3 Embolic Protection Device During TAVR: The REFLECT Trial

Presenter: Tamim Nazif

September 21, 2018

Presentation TCT 2018

Full Body Embolic Protection During TAVR (Filterlex)

Presenter: Giora Weisz

September 21, 2018

Presentation TCT 2018

TCT-16: Incidence, Outcomes, And Microbiologic Profile Of Prosthetic Valve Endocarditis After TAVR And SAVR: Insights From PARTNER

Presenter: Charles J. Davidson, Jeffrey J. Popma, Matthew Summers

September 21, 2018

Presentation TCT 2018

Bioprosthetic or Native Aortic Scallop Intentional Laceration to Prevent Iatrogenic Coronary Artery Obstruction During Transcatheter Aortic Valve Replacement: A Prospective IDE Trial (BASILICA)

Presenter: Jaffar M Khan

September 21, 2018

Presentation TCT 2018

TCT-15: Two-Year Outcomes After Transcatheter Aortic Valve Replacement With Mechanically- versus Self-Expandable Valves: Results From The REPRISE III Randomized Trial

Presenter: Charles J. Davidson, Jeffrey J. Popma, Michael J. Reardon

September 21, 2018

Presentation TCT 2018

Featured Lecture: Future Innovation in TAVR: Remaining Clinical Needs, Novel Technologies and Ancillary Device Strategies

Presenter: Dariusz Dudek, Ran Kornowski, Axel Linke, Martin B. Leon

September 21, 2018

Presentation TCT 2018

TCT-14: Final 5-Year Outcomes Of The REPRISE II Study: Long-Term Outcomes With the Fully Repositionable and Retrievable Lotus Transcatheter Aortic Valve

Presenter: Charles J. Davidson, Jeffrey J. Popma, Nicolas Dumontiel

September 21, 2018

Presentation TCT 2018

TCT-13: 5-Year Outcomes From the Randomized Corevalve USPivotal High Risk Trial: Final Results

Presenter: Charles J. Davidson, Jeffrey J. Popma, Thomas Gleason

September 21, 2018

Presentation TCT 2018

New TAVR Devices: VitaFlow, Venus A Plus, and Venibri

Presenter: Runlin Gao, Martin B. Leon, Junbo Ge

September 21, 2018

Presentation TCT 2018

Debate Con: TAVR for Moderate-Risk Patients: SAVR Remains First Line of Therapy!

Presenter: Jose Armando Mangione

September 21, 2018

Presentation TCT 2018

Debate Pro: TAVR for Moderate-Risk Patients: Ready for Prime Time!

Presenter: Gerardo Nau

September 21, 2018

Presentation TCT 2018

TAVR in the Patient With Atrial Fibrillation and Contraindications to Chronic Anticoagulation

Presenter: Anibal A. Damonte

September 21, 2018

Presentation TCT 2018

Complications of TAVR, Overview

Presenter: Philippe Genereux

September 21, 2018

Presentation TCT 2018

The TAVR Development from First in Man to Phase 3 and Beyond

Presenter: Robert O. Bonow, Stan Rowe, Martin B. Leon

September 21, 2018

Presentation TCT 2018

The TAVR Development from Concept to First in Man

Presenter: Robert O. Bonow, Stan Rowe, Alain G. Cribier

September 21, 2018

Presentation TCT 2018

Interpretation of Hemodynamic, CT, and Echo Data for TAVR Clinical Decision-Making

Presenter: Jeff Davis, Thomas H. Maloney, Azeem Latib

September 21, 2018

Presentation TCT 2018

Antithrombotic Therapy in Patients Undergoing TAVR

Presenter: Jeroen J. Bax, Stephan Windecker

September 21, 2018

Presentation TCT 2018

TAVR: New Indications and Unmet Needs

Presenter: Jeroen J. Bax, Stephan Windecker, Thomas Pilgrim

September 21, 2018

Presentation

Length of Stay and Discharge Disposition After TAVR and SAVR in the US

September 21, 2018

News Daily News

TAVR Superior to Surgery at Getting High-Risk Patients Home Sooner

Michael O'Riordan

September 20, 2018

Advertisement

Early Experiences with the New TriGUARD 3 Embolic Protection Device During TAVR: The REFLECT Trial

Full Body Embolic Protection During TAVR (Filterlex)

TCT-16: Incidence, Outcomes, And Microbiologic Profile Of Prosthetic Valve Endocarditis After TAVR And SAVR: Insights From PARTNER

Bioprosthetic or Native Aortic Scallop Intentional Laceration to Prevent Iatrogenic Coronary Artery Obstruction During Transcatheter Aortic Valve Replacement: A Prospective IDE Trial (BASILICA)

TCT-15: Two-Year Outcomes After Transcatheter Aortic Valve Replacement With Mechanically- versus Self-Expandable Valves: Results From The REPRISE III Randomized Trial

Featured Lecture: Future Innovation in TAVR: Remaining Clinical Needs, Novel Technologies and Ancillary Device Strategies

TCT-14: Final 5-Year Outcomes Of The REPRISE II Study: Long-Term Outcomes With the Fully Repositionable and Retrievable Lotus Transcatheter Aortic Valve

TCT-13: 5-Year Outcomes From the Randomized Corevalve USPivotal High Risk Trial: Final Results

New TAVR Devices: VitaFlow, Venus A Plus, and Venibri

Debate Con: TAVR for Moderate-Risk Patients: SAVR Remains First Line of Therapy!

Debate Pro: TAVR for Moderate-Risk Patients: Ready for Prime Time!

TAVR in the Patient With Atrial Fibrillation and Contraindications to Chronic Anticoagulation

Complications of TAVR, Overview

The TAVR Development from First in Man to Phase 3 and Beyond

The TAVR Development from Concept to First in Man

Interpretation of Hemodynamic, CT, and Echo Data for TAVR Clinical Decision-Making

Antithrombotic Therapy in Patients Undergoing TAVR

TAVR: New Indications and Unmet Needs

Length of Stay and Discharge Disposition After TAVR and SAVR in the US

TAVR Superior to Surgery at Getting High-Risk Patients Home Sooner

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content